# US 10,864,159 B2 · Method and composition for treating ocular hypertension and glaucoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,159 B2
- Document ID: US10864159B2
- Status: Granted
- Kind: B2
- Application number: 16/010,739
- Filed: 2018-06-18
- Published: 2018-10-11
- Granted: 2020-12-15
- Earliest claimed: 2008-05-30
- Assignees: Santen Pharmaceutical Co., Ltd.; AGC Inc.
- Applicants: Santen Pharmaceutical Co., Ltd.; AGC Inc.
- Inventors: Timo Reunamaki; Pertti Pellinen; Olli Oksala; Kari Lehmussaari
- Web page: https://patentgrep.com/patent/US10864159B2

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61P 9/12: Antihypertensives
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 47/02: Inorganic compounds
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to an ophthalmic aqueous composition containing PGF2α analogues for treating ocular hypertension and glaucoma, to a method for treating ocular hypertension and glaucoma by administering said composition to a subject in need of such treatment, and to a method for increasing aqueous solubility and stability of PGF2α analogues in an aqueous composition.

## Claims

### Claim 1

A method for treating ocular hypertension and glaucoma to a subject in need thereof, by administrating an ophthalmic aqueous solution consisting of 0.0015% w/v tafluprost as an active ingredient, 0.075% w/v polysorbate 80, 0.05% w/v disodium edetate, 2.25% w/v glycerol, 0.2% w/v sodium dihydrogen phosphate dihydrate, one or more pH adjusters, and water.

### Claim 2 (depends on 1)

A method for treating ocular hypertension and glaucoma to a subject in need thereof according to claim 1, wherein the ophthalmic aqueous solution is packaged in a single dose or unit dose container.

### Claim 3 (depends on 1)

A method for treating ocular hypertension and glaucoma to a subject in need thereof according to claim 1, wherein the ophthalmic aqueous solution is packaged in a container made of a low density polyethylene.

### Claim 4 (depends on 2)

A method for treating ocular hypertension and glaucoma to a subject in need thereof according to claim 2, wherein the container is made of a low density polyethylene.

### Claim 5 (depends on 4)

A method for treating ocular hypertension and glaucoma to a subject in need thereof according to claim 4, wherein the container contains no more than 10% of any material other than polyethylene.